Prevalence of dialysis-related amyloidosis in diabetic patients. Diabetes Amyloid Study Group.
It has recently been shown that beta 2-microglobulin isolated from amyloid deposits in dialysis patients is modified by advanced glycation (AGE). In this context it appeared of interest to examine in a cross-sectional multicentre study whether dialysis-related amyloidosis, as evaluated by X-ray assessment of cysts in the metacarpal bones, was different in diabetic patients on maintenance haemodialysis for more than 5 years time compared with matched non-diabetic controls. We evaluated the hand skeleton of 75 diabetic patients (9 type I, 66 type II; 35 male, 40 female; median age 64 years, range 31-86; median duration of dialysis 7 years, range 5-17). They were compared with 150 patients without diabetes mellitus who were matched for age, gender and duration of dialysis. Hand X-rays were centrally evaluated by one radiologist unaware of the underlying clinical diagnosis. The overall frequency of amyloid cysts was 9/75 (12%) in diabetic patients (95% confidence interval 4.6-19.3%) and 28/150 (19%) in matched controls (95% confidence interval 12.4-24.9%). The results indicate that diabetes mellitus does not confer an increased risk of dialysis-related amyloid cysts. The results are of interest with respect to the mechanism of amyloid formation.
Lehnert
H
H
Department of Internal Medicine, Heidelberg.
Jacob
C
C
Marzoll
I
I
Schmidt-Gayk
H
H
Stein
G
G
Ritz
E
E
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000686:Amyloidosis / Q000209:etiology* / Q000378:metabolism; D001845:Bone Cysts / Q000209:etiology / Q000378:metabolism; D001847:Bone Diseases / Q000209:etiology / Q000378:metabolism; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D003928:Diabetic Nephropathies / Q000150:complications* / Q000378:metabolism / Q000628:therapy*; D005260:Female; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006801:Humans; D008297:Male; D008663:Metacarpus; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*; D001613:beta 2-Microglobulin / Q000378:metabolism
D017127:Glycation End Products, Advanced; D001613:beta 2-Microglobulin